
Takafumi Koyama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/386590/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility and utility of a panel testing for 114 cancerâ€associated genes in a clinical setting: A hospitalâ€based study. Cancer Science, 2019, 110, 1480-1490.	3.9	238
2	First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3905-3915.	7.0	37
3	Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science, 2021, 112, 2361-2370.	3.9	33
4	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 95-105.	7.0	24
5	Firstâ€inâ€human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Science, 2020, 111, 571-579.	3.9	16
6	Firstâ€inâ€human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Science, 2021, 112, 1514-1523.	3.9	6
7	Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Japanese Journal of Clinical Oncology, 2021, 51, 1757-1760.	1.3	5
8	Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Medicine, 2021, 10, 6579-6589.	2.8	4
9	Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 1783-1791.	7.0	3